Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Pipeline Review, H2 2017’, provides in depth analysis on Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Hematological Disorders, Ophthalmology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders under development targeting Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AB Science SA

Almirall SA

Archer Pharmaceuticals Inc

Asana BioSciences LLC

Beijing Hanmi Pharmaceutical Co Ltd

Celgene Corp

Clevexel Pharma SAS

Fujifilm Corp

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Hutchison MediPharma Ltd

Japan Tobacco Inc

Levolta Pharmaceuticals Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Portola Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

TopiVert Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Overview 8

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 15

Products under Development by Universities/Institutes 22

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Therapeutics Assessment 24

Assessment by Mechanism of Action 24

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Companies Involved in Therapeutics Development 28

AB Science SA 28

Almirall SA 28

Archer Pharmaceuticals Inc 29

Asana BioSciences LLC 29

Beijing Hanmi Pharmaceutical Co Ltd 29

Celgene Corp 30

Clevexel Pharma SAS 30

Fujifilm Corp 31

Genosco Inc 31

Gilead Sciences Inc 32

GlaxoSmithKline Plc 33

Hutchison MediPharma Ltd 34

Japan Tobacco Inc 34

Levolta Pharmaceuticals Inc 35

Merck KGaA 35

Millennium Pharmaceuticals Inc 36

Portola Pharmaceuticals Inc 36

Rigel Pharmaceuticals Inc 37

TopiVert Ltd 38

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Drug Profiles 39

AB-8779 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

ASN-002 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

C-13 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

CC-509 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

cerdulatinib - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

CVXL-0074 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

entospletinib - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

FF-10102 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

fostamatinib disodium - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

GS-492429 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

GS-9876 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

GSK-2646264 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

HMPL-523 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

JTE-852 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

LAS-189386 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

nilvadipine - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

PRT-2761 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

SKIO-703 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Small Molecule to Inhibit SYK and JAK for Autoimmune Disorders and Oncology - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecule to Inhibit SYK for Inflammation - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Small Molecules to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

TAK-659 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

TOP-1210 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

TOP-1288 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

TOP-1630 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

TOP-1890 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Dormant Products 85

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Discontinued Products 88

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Product Development Milestones 89

Featured News & Press Releases 89

Nov 01, 2017: Takeda to Present Data On TAK-659 During 59th ASH Annual Meeting 89

Oct 03, 2017: Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia Phase 2 Study 89

Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP 90

Jul 19, 2017: Onyx helps accelerate TopiVert's compound to clinic 90

Jul 19, 2017: TopiVert Provides Update on TOP1630 91

Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL 91

Jun 22, 2017: Rigel Announces Oral Presentation of TAVALISSE Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress 92

Jun 19, 2017: FDA Accepts Rigels New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP 93

Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma 93

May 30, 2017: Asana BioSciences Initiates Phase 2 Evaluation of ASN002, a Novel SYK/JAK Inhibitor, in NHL, CLL and MF 94

May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 94

May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma 95

Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States 95

Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP 96

Mar 27, 2017: Asana BioSciences To Present New Data on ASN002 at AACR 2017 96

Appendix 97

Methodology 97

Coverage 97

Secondary Research 97

Primary Research 97

Expert Panel Validation 97

Contact Us 97

Disclaimer 98

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14

Number of Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 20

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 21

Number of Products under Investigation by Universities/Institutes, H2 2017 22

Products under Investigation by Universities/Institutes, H2 2017 23

Number of Products by Stage and Mechanism of Actions, H2 2017 24

Number of Products by Stage and Route of Administration, H2 2017 26

Number of Products by Stage and Molecule Type, H2 2017 27

Pipeline by AB Science SA, H2 2017 28

Pipeline by Almirall SA, H2 2017 28

Pipeline by Archer Pharmaceuticals Inc, H2 2017 29

Pipeline by Asana BioSciences LLC, H2 2017 29

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017 30

Pipeline by Celgene Corp, H2 2017 30

Pipeline by Clevexel Pharma SAS, H2 2017 31

Pipeline by Fujifilm Corp, H2 2017 31

Pipeline by Genosco Inc, H2 2017 32

Pipeline by Gilead Sciences Inc, H2 2017 33

Pipeline by GlaxoSmithKline Plc, H2 2017 34

Pipeline by Hutchison MediPharma Ltd, H2 2017 34

Pipeline by Japan Tobacco Inc, H2 2017 35

Pipeline by Levolta Pharmaceuticals Inc, H2 2017 35

Pipeline by Merck KGaA, H2 2017 36

Pipeline by Millennium Pharmaceuticals Inc, H2 2017 36

Pipeline by Portola Pharmaceuticals Inc, H2 2017 37

Pipeline by Rigel Pharmaceuticals Inc, H2 2017 38

Pipeline by TopiVert Ltd, H2 2017 38

Dormant Products, H2 2017 85

Dormant Products, H2 2017 (Contd..1), H2 2017 86

Dormant Products, H2 2017 (Contd..2), H2 2017 87

Discontinued Products, H2 2017 88

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 24

Number of Products by Routes of Administration, H2 2017 25

Number of Products by Stage and Routes of Administration, H2 2017 25

Number of Products by Stage and Molecule Type, H2 2017 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports